NCT03014362

Brief Summary

The purpose of this study is to determine if the use of Transcranial Magnetic Stimulation (TMS) provides rapid reduction and sustained attenuation of suicidal crisis. TMS is a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects than current treatments such as Electroconvulsive Therapy (ECT) and medication therapies. There will be 6 months of follow-up, in order to establish the ongoing and lasting therapeutic effect of TMS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2016

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 9, 2017

Completed
5 months until next milestone

Study Start

First participant enrolled

June 12, 2017

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 10, 2020

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 10, 2021

Completed
1 year until next milestone

Results Posted

Study results publicly available

September 28, 2022

Completed
Last Updated

September 28, 2022

Status Verified

September 1, 2022

Enrollment Period

2.6 years

First QC Date

November 30, 2016

Results QC Date

March 28, 2022

Last Update Submit

September 12, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Suicidal Ideation (Acute)

    The Beck Scale for Suicidal Ideation (SSI-T) is a 19-item clinician administered scale measuring current suicide ideation (SSI-C), suicide ideation at its worst point in the patient's life (SSI-W), and degree of hopelessness. The scale has been well validated. SSI-T scores range from 0-38, with higher scores indicating greater suicide risk.

    Change over the active treatment course ie. the 3 days of active treatment

Study Arms (2)

TMS active

ACTIVE COMPARATOR

Neuronetics NeuroStar XPLOR magnetic stimulator - Active; Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes. Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care).

Device: Neuronetics NeuroStar XPLOR magnetic stimulator - Active

TMS sham

SHAM COMPARATOR

Neuronetics NeuroStar XPLOR magnetic stimulator - Sham; Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.

Device: Neuronetics NeuroStar XPLOR magnetic stimulator - Sham

Interventions

Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes. Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.

TMS active

Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.

TMS sham

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may not qualify if:

  • Age 18 to 60
  • Able to speak and read English.
  • Combative with staff.
  • Comatose/catatonia.
  • Incapacity owing to active mania or psychosis.
  • Epilepsy, multiple sclerosis, or cerebrovascular accident.
  • Non-removable metal in the head (Shrapnel; plates, aneurysm coils/clips; metal tattoos etc.)
  • Implantable devices (pacemakers, stimulators, etc.)
  • Schizophrenic or borderline personality.
  • Positive screen for pregnancy.
  • Already receiving TMS as a treatment for depression.
  • Non-English reading and speaking subjects

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eisenhower Army Medical Center

Augusta, Georgia, 30905, United States

Location

Related Publications (1)

  • Hines CE, Mooney S, Watson NL, Looney SW, Wilkie DJ. Repetitive Transcranial Magnetic Stimulation Promotes Rapid Psychiatric Stabilization in Acutely Suicidal Military Service Members. J ECT. 2022 Jun 1;38(2):103-109. doi: 10.1097/YCT.0000000000000810.

MeSH Terms

Conditions

SuicideSuicidal IdeationSelf-Injurious Behavior

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Results Point of Contact

Title
Christopher E Hines, MD
Organization
Walter Reed National Military Medical Center

Study Officials

  • Christopher E Hines, MD

    Eisenhower Army Medical Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief, DDEAMC Outpatient Behavioral Health

Study Record Dates

First Submitted

November 30, 2016

First Posted

January 9, 2017

Study Start

June 12, 2017

Primary Completion

January 10, 2020

Study Completion

September 10, 2021

Last Updated

September 28, 2022

Results First Posted

September 28, 2022

Record last verified: 2022-09

Data Sharing

IPD Sharing
Will not share

Locations